HK1257679A1 - 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 - Google Patents

使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 Download PDF

Info

Publication number
HK1257679A1
HK1257679A1 HK19100043.6A HK19100043A HK1257679A1 HK 1257679 A1 HK1257679 A1 HK 1257679A1 HK 19100043 A HK19100043 A HK 19100043A HK 1257679 A1 HK1257679 A1 HK 1257679A1
Authority
HK
Hong Kong
Prior art keywords
phenylbutyrate
phenylacetate
ornithine
combination
neuronal cell
Prior art date
Application number
HK19100043.6A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher F. ROSE
Marc-André CLÉMENT
Cristina R. BOSOI
Mariana Macedo OLIVEIRA
Mélanie TREMBLAY
Chantal BÉMEUR
Original Assignee
Ocera Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics, Inc. filed Critical Ocera Therapeutics, Inc.
Publication of HK1257679A1 publication Critical patent/HK1257679A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK19100043.6A 2015-09-25 2016-09-22 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 HK1257679A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233002P 2015-09-25 2015-09-25
US201562233002P 2015-09-25
PCT/US2016/053176 WO2017053613A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (1)

Publication Number Publication Date
HK1257679A1 true HK1257679A1 (zh) 2019-10-25

Family

ID=58387333

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100043.6A HK1257679A1 (zh) 2015-09-25 2016-09-22 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失

Country Status (7)

Country Link
US (1) US20200206174A1 (enExample)
EP (1) EP3352748A4 (enExample)
JP (1) JP6989495B2 (enExample)
AU (1) AU2016325556B2 (enExample)
CA (1) CA2998490A1 (enExample)
HK (1) HK1257679A1 (enExample)
WO (1) WO2017053613A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
CA3004331A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
BR112020002419A2 (pt) 2017-08-14 2020-07-28 Axcella Health Inc. aminoácido para o tratamento de doença do fígado
CA3100944A1 (en) * 2018-05-22 2019-11-28 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
JP2022533569A (ja) * 2019-05-09 2022-07-25 オセラ セラピューティクス， インコーポレイテッド 肝性脳症を評価および処置する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
WO2006056794A1 (en) 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
SMT201700601T1 (it) * 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
EP2799067B1 (en) * 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate

Also Published As

Publication number Publication date
EP3352748A4 (en) 2019-06-05
WO2017053613A8 (en) 2017-04-27
AU2016325556A1 (en) 2018-03-01
WO2017053613A1 (en) 2017-03-30
US20200206174A1 (en) 2020-07-02
JP6989495B2 (ja) 2022-01-05
CA2998490A1 (en) 2017-03-30
JP2018531929A (ja) 2018-11-01
EP3352748A1 (en) 2018-08-01
AU2016325556B2 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
HK1257679A1 (zh) 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失
MX2018002320A (es) Abrazaderas quirurgicas de diseccion.
HK1246151A1 (zh) 为t细胞疗法而调理患者的方法
WO2016037138A8 (en) Globin gene therapy for treating hemoglobinopathies
AU2015214400B2 (en) Self-priming systems and methods
SG10201901010PA (en) Combination therapy for treating a paramyxovirus
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
EP3331459A4 (en) DEVICES, SYSTEMS, AND METHODS OF COLLECTION FOR USE IN BONE TISSUE
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
EP3520395A4 (en) OPTICAL SYSTEMS FOR SURGICAL PROBES, SYSTEMS AND METHODS THEREFOR AND METHOD FOR CARRYING OUT SURGICAL INTERVENTIONS
EP3434170A4 (en) ENDOSCOPE DEVICE, ENDOSCOPE SYSTEM, AND SURGICAL SYSTEM THEREFOR
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
EP3370633A4 (en) ORTHOPEDIC FASTENER, HOLDER AND GUIDANCE
WO2016055797A3 (en) Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
EP3745967A4 (en) DEVICES AND METHODS FOR TREATMENT OF BLOCKED BLOOD VESSELS
MX2025006207A (es) Composiciones que contienen arginasa i humana con un cofactor de metal de cobalto para usarse en el tratamiento de la deficiencia de arginasa 1
HK1258276A1 (zh) 用於治疗hiv的化合物和组合
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
EP3824989A4 (en) DISSOLVED DRAWING SUBSTANCE, TARGET SOLUTION AND FORWARD OSMOSIS WATER TREATMENT PROCESS
WO2016102930A3 (en) Medical device for treating a vein
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
WO2016127123A3 (en) Compounds and methods for preventing or treating sensory hair cell death
WO2015085314A3 (en) Methods for detection of heart failure
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
MX2018013507A (es) Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo.